To treat or not to treat: CFTR modulators after lung transplantation

Evidence for the extrapulmonary benefits of (CFTR) modulators is rapidly expanding. The use of CFTR modulators in CF patients who have undergone lung transplantation is not clear without guidance published in the medical literature to assist clinicians in the care of these patients. We discuss the potential benefits of CFTR modulators and provide insight into their use based on our experience in a small cohort of CF LTx recipients. We present pros and cons of CFTR modulator therapy for LTx recipients with CF. CFTR modulators should be considered in CF patients after lung transplantation for the time being until further research defines how to best use these therapies in transplant recipients.

[1]  G. Lam,et al.  The Extrapulmonary Effects of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Cystic Fibrosis , 2020, Annals of the American Thoracic Society.

[2]  P. Reix,et al.  Lumacaftor/ivacaftor initiation in two liver transplantation patients under tacrolimus and antifungal azoles , 2019, Clinical Case Reports.

[3]  P. Barry,et al.  CFTR modulator therapy in patients with cystic fibrosis and an organ transplant. , 2018, Paediatric respiratory reviews.

[4]  Gerald J Berry,et al.  Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. , 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.